Trending...
- Lyricalmar Set To Release Powerful New Ep "MARCHIVES" May 16
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
- How to Fast-Track Your Way to the Top with The Code
SEOUL, South Korea, April 30, 2025 ~ J INTS BIO, a leading company in the development of anticancer and orphan drugs, made significant announcements at the American Association for Cancer Research (AACR) 2025 conference in Chicago. The company presented its research findings on two promising treatments: 'JIN-A02', a next-generation EGFR-TKI therapeutic in clinical Phase 1/2 trials, and 'JIN-001', a potential treatment for ovarian cancer in preclinical stages.
The presentation by J INTS BIO attracted attention from both academia and the industry, showcasing the company's innovative drug development capabilities on a global stage. Professor Byoung Chul Cho from Yonsei Cancer Center presented a poster on the phase 1/2 clinical trial of 'JIN-A02', a next-generation oral EGFR-TKI.
'JIN-A02' has shown promising results in patients with non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases worldwide. In particular, it has shown remarkable efficacy in patients who have developed resistance to existing third-generation EGFR-TKIs. This is significant as there are currently no approved targeted therapies for patients with EGFR C797S mutation. The drug also demonstrated excellent safety profile with no dose-limiting toxicities or serious adverse events observed up to the 300 mg dose.
More on illi News
In one patient from the 300 mg cohort, complete clearance of circulating tumor DNA (ctDNA) harboring either the C797S or Ex19del mutation was observed, and ctDNA carrying the T790M mutation was reduced by over 90%. Additionally, there was a partial response (PR) with tumor size reductions of up to 39.7%, including shrinkage of intracranial metastatic lesions. These results are particularly significant for NSCLC patients who often develop brain metastases.
Currently, 'JIN-A02' is undergoing multinational clinical trials in Korea, the United States, Thailand, and other countries. It is being closely monitored as a potential groundbreaking treatment option for EGFR-mutant NSCLC patients.
Another promising drug presented by J INTS BIO was 'JIN-001', a second-generation synthetic HSP90 inhibitor developed to overcome resistance to existing ovarian cancer treatments. Ovarian cancer is one of the deadliest gynecological malignancies, often diagnosed at an advanced stage with limited treatment options.
More on illi News
In preclinical studies, 'JIN-001' showed significant enhancement of tumor suppression when combined with the chemotherapeutic agent cisplatin compared to cisplatin alone. Even at low concentrations, it demonstrated enhanced antitumor activity against both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. The combination therapy also reduced the expression of key signaling proteins related to cisplatin resistance, leading to sustained antitumor effects.
Based on these promising results, J INTS BIO plans to conduct additional preclinical studies and move 'JIN-001' into clinical trials with the goal of establishing a new standard of care for refractory and multidrug-resistant ovarian cancer.
The company's presentation at AACR 2025 highlights its commitment to strengthening its position in the global oncology market and becoming a leader in next-generation anticancer drug development. J INTS BIO aims to continue delivering innovative therapies through ongoing research and development efforts, offering hope to cancer patients worldwide.
The presentation by J INTS BIO attracted attention from both academia and the industry, showcasing the company's innovative drug development capabilities on a global stage. Professor Byoung Chul Cho from Yonsei Cancer Center presented a poster on the phase 1/2 clinical trial of 'JIN-A02', a next-generation oral EGFR-TKI.
'JIN-A02' has shown promising results in patients with non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases worldwide. In particular, it has shown remarkable efficacy in patients who have developed resistance to existing third-generation EGFR-TKIs. This is significant as there are currently no approved targeted therapies for patients with EGFR C797S mutation. The drug also demonstrated excellent safety profile with no dose-limiting toxicities or serious adverse events observed up to the 300 mg dose.
More on illi News
- Indie Game Publisher Joins Federal Lawsuit Challenging Trump Administration's Illegal Tariffs
- Care Dental Implant & Cosmetic Center's New Website Launch!
- $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
- YMCA Seeks to Expand Civic Leadership Opportunities for More New Jersey Youth
- Swim Stroke Doctor, Secures Patent for Groundbreaking Swim Cap That Improves Performance Through
In one patient from the 300 mg cohort, complete clearance of circulating tumor DNA (ctDNA) harboring either the C797S or Ex19del mutation was observed, and ctDNA carrying the T790M mutation was reduced by over 90%. Additionally, there was a partial response (PR) with tumor size reductions of up to 39.7%, including shrinkage of intracranial metastatic lesions. These results are particularly significant for NSCLC patients who often develop brain metastases.
Currently, 'JIN-A02' is undergoing multinational clinical trials in Korea, the United States, Thailand, and other countries. It is being closely monitored as a potential groundbreaking treatment option for EGFR-mutant NSCLC patients.
Another promising drug presented by J INTS BIO was 'JIN-001', a second-generation synthetic HSP90 inhibitor developed to overcome resistance to existing ovarian cancer treatments. Ovarian cancer is one of the deadliest gynecological malignancies, often diagnosed at an advanced stage with limited treatment options.
More on illi News
- Anern Launches New Generation of Lithium Solar Batteries, Empowering a Smarter, Greener Future
- K2 Integrity and the Institute for Financial Integrity Launch AML/CFT Course for Investment Advisers
- Buttcoin - The Next Bitcoin Foundation Explores First Spot Buttcoin ($BUTTCOIN) ETP Listing on Switzerland's SIX Exchange
- Start Dogecoin cloud mining with XY Miners and maximize your passive income
- New Report Highlights the Most Dangerous States for Transportation and Warehouse Workers
In preclinical studies, 'JIN-001' showed significant enhancement of tumor suppression when combined with the chemotherapeutic agent cisplatin compared to cisplatin alone. Even at low concentrations, it demonstrated enhanced antitumor activity against both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. The combination therapy also reduced the expression of key signaling proteins related to cisplatin resistance, leading to sustained antitumor effects.
Based on these promising results, J INTS BIO plans to conduct additional preclinical studies and move 'JIN-001' into clinical trials with the goal of establishing a new standard of care for refractory and multidrug-resistant ovarian cancer.
The company's presentation at AACR 2025 highlights its commitment to strengthening its position in the global oncology market and becoming a leader in next-generation anticancer drug development. J INTS BIO aims to continue delivering innovative therapies through ongoing research and development efforts, offering hope to cancer patients worldwide.
Filed Under: Business
0 Comments
Latest on illi News
- RallyCap Sports Launches New Illinois Chapter: Inclusive Sports Coming to Sheridan!
- Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit
- Twitter's Buzzing! What's the Deal with PhotoG, the AI Everyone's Talking About?
- New WHO Mental Health Guidelines Condemn Coercive Psychiatry
- GlycoNex Presents Preclinical Data on GNX1021 at AACR Annual Meeting 2025
- Keenan's Caring Konnections, LLC
- Celebrate Children's Day in Tochigi City!
- Mensa identifies best board games of 2025
- Workforce Housing Leader Offers Solution to Protect $160B Annual Federal Savings Found by Elon Musk
- Deevid AI Launches New Ghibli AI Generator: Transform Images into Studio Ghibli-Style Masterpiec
- Over $261 Billion in Federal Housing Funds Misaligned: New Housing Governance System Launches
- Costa Rica's Rainy Season Brings a Surge in Sportfishing Action and Travel Deals
- Rubber-Inc Delivers Stability, Speed, and Solutions in an Uncertain Market
- The International Fellowship of Christians and Jews Partners with The Jerusalem Post to Launch New Podcast Series Titled, 'Good for the Jews? Inside Christian Zionism'
- City Of Chicago Celebrates Arbor Day with Tree-Planting Event
- Chicago: Mayor Johnson Announces $2 Million In New Round of Community Grant Recipients
- People & Stories/Gente y Cuentos Announces New Board Leadership & Corporate Partnership Initiative
- Concert Violinist Addison Teng Redefines Music Education for a New Generation
- How to Fast-Track Your Way to the Top with The Code
- Azitra, Inc. to Present ATR-04 Program Update at ASCO 2025